All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species
Advanced Science · 2026-08 · 13 (45)
DOI: 10.1002/advs.76049 ↗At a glance
Journal article in Advanced Science, published online on 2026-06-11. Written by Luxiang Zhao and 8 co-authors. Institution: College of Mechanical and Electrical Engineering, Beijing University of Chemical Technology, Chaoyang, Beijing, China. Major MEDLINE topics: Plasma Gases, Reactive Oxygen Species, Reactive Nitrogen Species, Drug Delivery Systems. 91 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National Key Research and Development Program of China.
Abstract (original language)
Wearable cold atmospheric plasma (CAP) systems hold promise for oncology, but clinical translation has been hindered by limited flexibility, suboptimal skin contact, and insufficient mechanistic evidence. Here, we report an All‐Flex Plasma Patch (AFPP), a fully stretchable CAP platform capable of ambient‐air operation, designed for non‐invasive, safe, and effective cancer therapy. In a subcutaneous melanoma model, one‐week AFPP treatment drives pronounced tumor regression, achieving only 1/19 of the tumor volume observed in control group. The device demonstrates enhanced transdermal penetration of reactive oxygen and nitrogen species (RONS) compared with rigid plasma sources, indicating its potential as a cross‐barrier delivery system with excellent biocompatibility and minimal systemic burden. Moreover, we identify adverse responses under excessive exposure and outline an initial therapeutic range balancing efficacy and potential side effects, highlighting its low side effects under optimized conditions. Utilizing this platform, we systematically reveal that AFPP treatment regulates multiple previously unreported key proteins, drives metabolic reprogramming and disrupts calcium homeostasis, and it inhibits tumor progression by orchestrating multiple cell death modalities. This work provides preliminary mechanistic insights supporting the development of safe and effective wearable CAP therapy, and outlines a framework relevant to the translational advancement of non‐invasive plasma oncology as a complement to conventional treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Mechanical and Electrical Engineering, Beijing University of Chemical Technology, Chaoyang, Beijing, China.
- Department of Laboratory Medicine, State Key Laboratory of Vascular Homeostasis and Remodeling, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, National Health Commission, Peking University T…
Funding
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program of China
- Beijing Natural Science Foundation
- Beijing Nova Program
- China Scholarship Council, Key Clinical Projects of Peking University Third Hospital
- Research Project of Peking University Third Hospital in State Key Laboratory of Vascular Homeostasis and Remodeling
- Supported by Beijing Natural Science Foundation
Cite
APA
Zhao, L., Tuergong, A., Yang, H., Xue, S., Yan, A., Wang, M., Song, W., Si, W., & Wang, R. (2026). All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species. Advanced Science, 13(45). https://doi.org/10.1002/advs.76049
Vancouver
Zhao L, Tuergong A, Yang H, Xue S, Yan A, Wang M, et al. All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species. Advanced Science. 2026;13(45). doi:10.1002/advs.76049
BibTeX
@article{Zhao2026,
author = {Zhao, Luxiang and Tuergong, Abulaihaiti and Yang, Hanshu and Xue, Shuang and Yan, An and Wang, Mingzhen and Song, Weilong and Si, Wenzhe and Wang, Ruixue},
title = {All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {45},
doi = {10.1002/advs.76049}
}
EUVIMED